FOXO1 and type 1 diabetes mellitus: Our recent study demonstrated that activation of FoxO1 via stimulating the expression of PDK4 and CPT led to imbalanced oxidative metabolism which may exacerbate the progress of DCM in streptozotocin-induced type 1 diabetes in rats and such disadvantageous effects like mitochondrial and cardiac dysfunction is reversible by administration of AS1842856 (AS), a selective FoxO1-selective inhibitor (15).